Purpose: To investigate the optimal schemes of prostate biopsy according to prostate volume (PV), age and transrectal ultrasound (TRUS) status in Chinese men. Methods: 923 consecutive patients who underwent initial TRUS-guided systematic 12-core prostate biopsy (12PBx) were enrolled in this study. The 12PBx was obtained by overlapping of conventional sextant, lateral base, mid-gland of peripheral zone and apex. Each sample was individually marked and inked before fixation. Patients were divided into 8 subgroups on the basis of independent risk factors investigated using logistic regression model. Subsequently, 12PBx was defined as self-control for the analysis of biopsy schemes (6-, 8- and 10PBx) on individual core basis. The prostate cancer detection rates (CDRs) of 6-, 8-, 10- and 12PBx were compared for each individual subgroup. Results: The 12PBx detected 253 (27.4%) cases of prostate cancer (PCa), of which 67.2, 47.1 and 61.3% were located in the base, mid-gland and apex, respectively. Multivariate analysis indicated that age, TRUS status and PV were independent risk factors for PCa detection. CDR increased with increasing biopsy cores. However, for patients with age ≥65 years, positive TRUS and PV <38.5 cm3, CDR of 8PBx (30.6%) was similar to 10PBx (32.2%) and 12PBx (32.2%); for patients with age ≥65 years, negative TRUS and PV <38.5 cm3 or ones with age ≥65 years, positive TRUS and PV ≥38.5 cm3, 10PBx was as effective as 12PBx in detecting PCa (27.8, 27.5 vs. 28.9, 29.3%, respectively). Conclusion: Age, TRUS status and PV were independent risk factors for PCa detection. Traditional sextant biopsy is not recommended. 8-, 10-, or 12PBx as an individual biopsy scheme might be adopted according to these risk factors for Chinese patients.

Keywords:
Prostate biopsy, Chinese men, Prostate cancer, Optimal scheme
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
2.
Ta S, Klausner AP, Savage SJ, Unger P, Bar-Chama N: Male infertility due to a benign prostatic polyp. J Urol 2000;164:1659–1660.
3.
Hodge KK, McNeal JE, Stamey TA: Ultrasound guided transrectal core biopsies of the palpably abnormal prostate. J Urol 1989;142:66–70.
4.
Guichard G, Larre S, Gallina A, Lazar A, Faucon H, Chemama S, Allory Y, Patard JJ, Vordos D, Hoznek A, Yiou R, Salomon L, Abbou CC, de la Taille A: Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol 2007;52:430–435.
5.
Kawakami S, Okuno T, Yonese J, Igari T, Arai G, Fujii Y, Kageyama Y, Fukui I, Kihara K: Optimal sampling sites for repeat prostate biopsy: a recursive partitioning analysis of three-dimensional 26-core systematic biopsy. Eur Urol 2007;51:675–682, discussion 682–673.
6.
Scattoni V, Raber M, Abdollah F, Roscigno M, Deho F, Angiolilli D, Maccagnano C, Gallina A, Capitanio U, Freschi M, Doglioni C, Rigatti P, Montorsi F: Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010;57:1–8.
7.
Ploussard G, Xylinas E, Salomon L, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A: The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur Urol 2009;56:891–898.
8.
Matsumoto K, Satoh T, Egawa S, Shimura S, Kuwao S, Baba S: Efficacy and morbidity of transrectal ultrasound-guided 12-core biopsy for detection of prostate cancer in Japanese men. Int J Urol 2005;12:353–360.
9.
Kim JW LH, Hong SJ, Chung BH: Can a 12 core prostate biopsy increase the detection rate of prostate cancer versus 6 core? A prospective randomized study in Korea. Yonsei Med J 2004;45:671–675.
10.
Suzuki H, Komiya A, Kamiya N, Imamoto T, Kawamura K, Miura J, Suzuki N, Nakatsu H, Hata A, Ichikawa T: Development of a nomogram to predict probability of positive initial prostate biopsy among Japanese patients. Urology 2006;67:131–136.
11.
Abd TT, Goodman M, Hall J, Ritenour CW, Petros JA, Marshall FF, Issa MM: Comparison of 12-core versus 8-core prostate biopsy: multivariate analysis of large series of US veterans. Urology 2011;77:541–547.
12.
Gu F: Epidemiological survey of benign prostatic hyperplasia and prostatic cancer in China. Chin Med J (Engl) 2000;113:299–302.
13.
Shim HB, Park HK, Lee SE, Ku JH: Optimal site and number of biopsy cores according to prostate volume prostate cancer detection in Korea. Urology 2007;69:902–906.
14.
Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S, Saito K, Fujii Y, Yonese J, Masuda H, Kihara K, Fukui I: Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 2008;54:601–611.
15.
Dai B, Ye DW, Kong YY, Shen YJ, Wang BH: Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl 2008;10:325–331.
16.
Zaytoun OM, Kattan MW, Moussa AS, Li J, Yu C, Jones JS: Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. Urology 2011;78:392–398.
17.
Gao HW, Li YL, Wu S, Wang YS, Zhang HF, Pan YZ, Zhang L, Tateno H, Sato I, Kuwahara M, Zhao XJ: Mass screening of prostate cancer in a Chinese population: The relationship between pathological features of prostate cancer and serum prostate specific antigen. Asian J Androl 2005;7:159–163.
18.
Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LF, Lein M, Sinha P, Loening SA, Jung K: Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48:1279–1287.
19.
Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H, de la Roza G: Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007;99:1484–1489.
20.
Scattoni V, Zlotta A, Montironi R, Schulman C, Rigatti P, Montorsi F: Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Eur Urol 2007;52:1309–1322.
21.
Meng MV, Franks JH, Presti JC Jr, Shinohara K: The utility of apical anterior horn biopsies in prostate cancer detection. Urol Oncol 2003;21:361–365.
22.
Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawin KM: Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. J Urol 2004;171:1089–1092.
23.
Iremashvili V, Pelaez L, Jorda M, Manoharan M, Arianayagam M, Rosenberg DL, Soloway MS: Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology 2012;79:37–42.
24.
Neill MG, Toi A, Lockwood GA, Evans A, Tammsalu L, Fleshner NE: Systematic lateral prostate biopsy – are the benefits worth the costs? J Urol 2008;179:1321–1326.
25.
Luciani LG, De Giorgi G, Valotto C, Zanin M, Bierti S, Zattoni F: Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/ml and abnormal digital rectal examination findings. Urology 2006;67:555–558.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.